Brazil's GLP-1 Black Market Booms: 83 Deaths Probed, Half of $7B Sales Untracked
LLY sits 64% above its 52-week low of $712.05.
Summary
Reuters reports a thriving black market for weight-loss drugs in Brazil, with 83 deaths under investigation and over 3,600 complications linked to GLP-1s. About 51% of Brazil's estimated $7 billion weight-loss drug sales this year are expected to come from compounded or smuggled products, bypassing regulated channels. Eli Lilly's Mounjaro is explicitly named as a target of smuggling and counterfeiting. The company says it supports authorities in combating the illegal market. This raises regulatory and reputational risk for Lilly in a key growth market, though the direct financial impact on branded sales is unclear.
At the time of this announcement, LLY was trading at $1,170.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.